ATE200224T1 - Neue medizinische zusammensetzung - Google Patents

Neue medizinische zusammensetzung

Info

Publication number
ATE200224T1
ATE200224T1 AT93916170T AT93916170T ATE200224T1 AT E200224 T1 ATE200224 T1 AT E200224T1 AT 93916170 T AT93916170 T AT 93916170T AT 93916170 T AT93916170 T AT 93916170T AT E200224 T1 ATE200224 T1 AT E200224T1
Authority
AT
Austria
Prior art keywords
ych3
medical composition
new medical
integer
ych
Prior art date
Application number
AT93916170T
Other languages
English (en)
Inventor
Yasuhiko Koezuka
Koji Kabaya
Kazuhiro Motoki
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of ATE200224T1 publication Critical patent/ATE200224T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT93916170T 1992-07-16 1993-07-15 Neue medizinische zusammensetzung ATE200224T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21201592 1992-07-16
JP8521993 1993-03-19
PCT/JP1993/000984 WO1994002168A1 (fr) 1992-07-16 1993-07-15 Nouvelle composition medicamenteuse

Publications (1)

Publication Number Publication Date
ATE200224T1 true ATE200224T1 (de) 2001-04-15

Family

ID=26426239

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93916170T ATE200224T1 (de) 1992-07-16 1993-07-15 Neue medizinische zusammensetzung

Country Status (12)

Country Link
US (3) US5767092A (de)
EP (1) EP0650732B1 (de)
JP (1) JP3088461B2 (de)
KR (1) KR100277621B1 (de)
CN (1) CN1084623C (de)
AT (1) ATE200224T1 (de)
AU (1) AU684466B2 (de)
CA (1) CA2140013C (de)
DE (1) DE69330096T2 (de)
FI (1) FI950166A7 (de)
TW (1) TW261533B (de)
WO (1) WO1994002168A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5849716A (en) * 1992-10-22 1998-12-15 Kirin Beer Kabushiki Kaisha Sphingoglycolipids, their preparation, and therapeutic methods of use
ATE176237T1 (de) * 1993-04-15 1999-02-15 Kirin Brewery Sphingoglycolipid und verwendung davon
US6026815A (en) * 1996-10-10 2000-02-22 Gholam A. Peyman Radiopaque liquid as radiation blocking agent
JP2002226377A (ja) * 1996-10-14 2002-08-14 Kirin Brewery Co Ltd 配糖体含有末梢血幹細胞増加剤
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
CN1121223C (zh) * 1997-02-05 2003-09-17 麒麟麦酒株式会社 含有神经鞘糖脂的冷冻干燥组合物及其制造方法
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
ES2235324T3 (es) 1997-04-10 2005-07-01 Kirin Beer Kabushiki Kaisha Empleo de a-glicosilceramidas para la obtencion de un agente terapeutico para enfermedades autoinmunes.
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
AU2001268564A1 (en) * 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1437358B1 (de) * 2001-08-16 2006-10-18 Daiichi Asubio Pharma Co., Ltd. Neues glykolipid, und heilmittel für autoimmunerkrankungen, das dieses als wirkstoff enthält
US8443383B2 (en) * 2002-05-03 2013-05-14 Time Warner Cable Enterprises Llc Use of messages in program signal streams by set-top terminals
EP1541153A1 (de) * 2002-09-20 2005-06-15 Kirin Beer Kabushiki Kaisha Hepatitis-c-virus-inhibitor mit alpha-glycosylceramid als wirkstoff
WO2004094444A1 (en) * 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
US7309015B2 (en) * 2004-07-14 2007-12-18 Scanbuy, Inc. Mobile device gateway providing access to instant information
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
TWI382843B (zh) 2004-10-07 2013-01-21 Argos Therapeutics Inc 成熟樹突細胞組合物及培養彼等之方法
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
US7534434B2 (en) * 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
EP1848813B1 (de) 2005-01-28 2013-04-10 Brigham Young University Aktivierung von bakteriellem glycolipid von cd1d-begrenzten nkt-zellen
US20090036658A1 (en) * 2005-03-04 2009-02-05 The Regents Of The University Of California Highly efficient synthesis of alpha-O-galactosyl ceramides
BRPI0612732A2 (pt) * 2005-07-01 2011-08-16 Japan As Represented By The President Of Nat Ct Of Neurology And Psychiatry derivado de glicolipìdeo e uso do mesmo
EP1776963A1 (de) 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramiden als Adjuvantien und ihre Verwendung in pharmazeutischen Zusammensetzungen
US20070231344A1 (en) * 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
BRPI0710668A2 (pt) * 2006-04-07 2011-08-16 Scripps Res Insittute alfa-galactosil ceramidas modificadas para marcar e estimular células t matadoras naturais
CA2655947C (en) * 2006-06-30 2016-08-02 The Scripps Research Institute Compositions comprising nkt cell agonist compounds and methods of use
US8263576B2 (en) * 2006-08-15 2012-09-11 Mayo Foundation For Medical Education And Research Non-natural sphingolipid analogs and uses thereof
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
CA2702344C (en) * 2007-10-12 2016-09-27 Luigi Panza Analogues of glycolipids useful as immunoadjuvants
EP2058011A1 (de) * 2007-11-07 2009-05-13 Wittycell NKT-Zellen aktivierende, kovalent gebundene Glykolipid-Antigene und/oder Arzneimittel
PT2231145E (pt) * 2007-12-05 2014-12-23 Wittycell Utilização de glicosilceramidas para aumentar a resposta imunitária a antigénios
JP5809560B2 (ja) * 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
SMT201700203T1 (it) 2009-02-16 2017-05-08 Cerenis Therapeutics Holding Sa Mimetici di apolipoproteina a-i
SG2014012850A (en) 2010-10-18 2014-05-29 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
US10813950B2 (en) 2010-12-02 2020-10-27 Riken Immunotherapy using allo-NKT cells, cells for immunotherapy in which alpha chain of t-cell receptor (TCR) gene has been rearranged to uniform Vα-Jα, and banking of NKT cells derived from said cells
US10227290B2 (en) 2012-02-07 2019-03-12 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
JP6283809B2 (ja) 2012-08-22 2018-02-28 株式会社レグイミューン Ｉ型糖尿病の予防又は治療のための製剤
CA2925878A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
CN105120877A (zh) 2012-11-05 2015-12-02 株式会社雷吉姆恩 免疫耐受诱导物
WO2014079946A1 (en) 2012-11-21 2014-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the risk of acute graft versus host disease
JP2015205835A (ja) * 2014-04-21 2015-11-19 国立大学法人福井大学 中性子線障害防護剤
IL303285A (en) 2020-12-04 2023-07-01 Regimmune Corp Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622666A (en) * 1968-03-04 1971-11-23 Stanley Drug Products Inc Methods for treating bacterial infections with phrenosin
US4598051A (en) * 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4806466A (en) * 1981-10-29 1989-02-21 The Regents Of The University Of California Cell agglutination reagent comprising conjugates of antibody covalently bound to liposomes
IT1168205B (it) * 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
EP0146810A3 (de) * 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
JPS6157594A (ja) * 1984-08-30 1986-03-24 Suntory Ltd ガラクトスフインゴ脂質及びその製造法
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
DD261165A5 (de) * 1985-08-13 1988-10-19 Solco Basel Ag,Ch Neues verfahren zur herstellung von sphingosinderivaten
JPH07116209B2 (ja) * 1986-04-11 1995-12-13 メクト株式会社 シアロシルセラミド類及びその製造方法
US4990603A (en) * 1986-07-04 1991-02-05 Mect Corporation Sialic acid derivatives and process therefor
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4937232A (en) * 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
JPS6495A (en) * 1986-12-19 1989-01-05 Tosoh Corp Alpha-glycosyl ceramide derivative
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
JP2588729B2 (ja) * 1987-10-05 1997-03-12 塩野義製薬株式会社 スフィンゴシン誘導体
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
JP2631532B2 (ja) * 1988-10-14 1997-07-16 富士写真フイルム株式会社 熱転写受像材料
DE3840044A1 (de) * 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
IT1235162B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5028715A (en) * 1989-02-06 1991-07-02 Southwest Research Institute Radioprotective agents and their method of manufacture
US5210073A (en) * 1989-09-29 1993-05-11 Ajinomoto Co., Inc. Method for treating cancer therapy radiation damage or arteriosclerosis using human adf
JP3068910B2 (ja) 1990-11-08 2000-07-24 麒麟麦酒株式会社 新規スフィンゴ糖脂質、その製造法および使用
JPH06145189A (ja) * 1991-01-23 1994-05-24 Kitasato Inst:The スフィンゴ糖脂質
JP3034650B2 (ja) * 1991-06-19 2000-04-17 株式会社ジーシー 歯質用接着剤
JPH0559081A (ja) * 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
ATE176237T1 (de) * 1993-04-15 1999-02-15 Kirin Brewery Sphingoglycolipid und verwendung davon

Also Published As

Publication number Publication date
TW261533B (de) 1995-11-01
CN1088093A (zh) 1994-06-22
FI950166A7 (fi) 1995-01-31
HK1009937A1 (en) 1999-09-17
US5767092A (en) 1998-06-16
AU4583593A (en) 1994-02-14
CN1084623C (zh) 2002-05-15
US6071884A (en) 2000-06-06
EP0650732A4 (de) 1998-04-01
EP0650732A1 (de) 1995-05-03
CA2140013A1 (en) 1994-02-03
AU684466B2 (en) 1997-12-18
WO1994002168A1 (fr) 1994-02-03
CA2140013C (en) 2002-08-27
US6017892A (en) 2000-01-25
KR950702431A (ko) 1995-07-29
FI950166A0 (fi) 1995-01-13
DE69330096T2 (de) 2001-10-18
EP0650732B1 (de) 2001-04-04
JP3088461B2 (ja) 2000-09-18
KR100277621B1 (ko) 2001-02-01
DE69330096D1 (de) 2001-05-10

Similar Documents

Publication Publication Date Title
ATE200224T1 (de) Neue medizinische zusammensetzung
FI941986A0 (fi) Antifungaaliset tri-substituoidut tetrahydrofuraanit
DE69319380D1 (de) Azolverbindungen, deren Herstellung und Verwendung
ATE125539T1 (de) 1,4-benzothiazedinderivat.
ATE161873T1 (de) Strahlungshärtbare zusammensetzungen
EP0632031A4 (de)
ES2072223B1 (es) Liposomas encapsulando doxorubicina.
NO922674D0 (no) Spikamycinderivater og anvendelse derav
ATE153666T1 (de) Phosphono-arylethanolamin-verbindungen mit antihyperglykämischer und/oder antiobeser wirkung
ATE109770T1 (de) Derivate der coffeinsäure und pharmazeutische zusammensetzungen, die sie enthalten.
EP0712398A1 (de) Benzopyrane und diese enthaltende pharmazeutische zusammenstellungen
DE68904018D1 (de) Antihypercholesterolemische 4,5-diaryl-2-substituierte thioimidazole.
FI904512A0 (fi) Menetelmä lääkeaineina käytettävien 1,3-tiatsolidinien -karbonyylikarboksiamidien valmistamiseksi
HUT49887A (en) Process for producing new cefem compounds
GR3024867T3 (en) Benzothiazole derivative
CA2052020A1 (en) Pradimicin derivatives
TW218020B (en) A protective agent against irradiation damage
MY115174A (en) N-hydroxyureas as antiinflammatory agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties